ReviewCureus2025
Next-Generation Moses Pulse Modulation: An Evaluation of Whether This Is Hype or Breakthrough.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation Moses™ technology is a pulse modulation modality of the traditional holmium yttrium-aluminum-garnet (YAG) laser and has been developed for use in both laser lithotripsy and prostate enucleation. In traditional holmium YAG lasers, the energy is delivered in a single continuous pulse, which can be less efficient in terms of stone fragmentation and tissue interaction. Moses technology, on the other hand, uses multiple, shorter pulses within a single laser firing cycle, which makes the energy delivery more controlled and effective. In pre-clinical studies, Moses™ technology has been shown to improve stone fragmentation efficiency in lithotripsy and reduce overall procedure time in prostate enucleation. Given its relatively recent introduction, it is still unclear if use of Moses™ can translate to efficiency and time savings in the operating room. The aim of this narrative review is to summarise the latest evidence for use of Moses™ technology in the treatment of urolithiasis and prostate enucleation. To compare Moses™ to standard holmium, a literature review was conducted in PubMed and Embase for randomised controlled trials and cohort studies. For laser lithotripsy, outcomes investigated were overall procedure time, fragmentation time, degree of retropulsion, stone-free rate and complications. For prostate enucleation, the outcomes were operative time and haemostasis time. This review summarises current comparative findings between Moses™ and conventional holmium:YAG laser in the context of lithotripsy and prostate enucleation, highlighting consistent advantages in key operative metrics across both applications. Current literature evidence suggests Moses™ technology is associated with superior outcomes compared to standard holmium YAG laser in several key parameters determining the overall efficiency. For urolithiasis, Moses™ could offer shorter procedure times and for prostate enucleation, it could reduce the learning curve of HoLEP, enabling it to become an outpatient-based procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.